Literature DB >> 6259608

[Cefotaxime in childhood infections (author's transl)].

J M Garnier, F Giraud.   

Abstract

Cefotaxime was administered to 20 patients suffering from severe bacterial infections. Four were newborn babies, seven were infants, and nine were children. The infections treated included 9 bronchopulmonary infections and 6 urinary tract infections. In 9 patients, the infecting organism was identified: E. coli (3), Klebsiella (2), Staphylococcus aureus (3), and Proteus (1). Except in one case, cefotaxime was administered alone at doses of 50 to 100 mg/kg every 12 hours. The route of administration was intramuscular. 4 patients had already received unsuccessful antimicrobial therapy. All patients were clinically cured. In those with pneumonia, the clinical and radiological response was very prompt; in urinary tract infections, the temperature returned to normal in less than 48 hours. The local and general tolerance was always good. It may be concluded from these results that cefotaxime, a new parenteral cephalosporin, is especially useful and should prove particularly effective in severe infectious conditions found in pediatric practice.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6259608

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  3 in total

Review 1.  Treatment and prevention of pertussis by antimicrobial agents (Part II).

Authors:  J E Hoppe; A Haug
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

Review 2.  Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.

Authors:  G L Kearns; R A Young; R F Jacobs
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

Review 3.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.